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INTRODUCTION: 
There are a number carriers – Microspheres1, 
nanoparticles, liposomes and others for which optimized 
technologies are under development to a) enhance the 
performance of products that have already been delivered 
with some success via that route and b) modulates the 
release and absorption characteristics of the drugs 
particularly those drugs which have shorter biological half 
life. Dosage forms that can precisely control the release 
rates and target drugs to a specific body site have created 
enormous impact on the formulation and development of 
novel drug delivery systems 2. Controlled drug delivery 
occurs when a polymer, whether natural or synthetic, is 
judiciously combined with a drug or other active agent in 
such a way that the active agent is released from the 
material in a predesigned manner 3, 4.  
Microspheres constitute an important part of these 
particulate DDS by virtue of their small size and efficient 
carrier characteristics. Microspheres have many 
applications in medicine, with the main uses being for the 
encapsulation of drugs and proteins. Microparticulate 
systems can be made by various techniques involving 
physicochemical processes (solvent evaporation method, 
phase separation method) and mechanical processes (e.g., 
spray drying) 5. 
Of course, microspheres technology faces significant 
challenges. They include: accurately targeting the correct 
sites; increasing loading efficiency; the incorporation of 
optimum drug release kinetics and avoiding dose dumping. 
The formulation variables have a variety of effects on the 
physicochemical properties of the microspheres. The bio-
distribution of the drug from microspheres is highly 
dependent on the size and % drug entrapment of the 
microspheres. Release kinetics of the microsphere matrix 
is depend on the various factors i.e. type of polymer used 1, 
concentration of polymer 1, 6-10, drug to polymer ratio, 
solubility of drug, dispersed phase to continuous phase 
ratio etc. These variables also affect the loading efficiency 
of the microspheres. Drug released from a microsphere can 
occurs in different way i.e. erosion, diffusion, swelling. 
Since the rate of drug release is controlled by the various 
factors, it is important to understand the physical and 
chemical properties of the releasing medium. Thus present 
review explains the effects of various variables on the 
characteristics of the release process. Additionally this also 
summarized the method of preparation and 
characterization of microspheres. 
1.  PREPARATION OF MICROSPHERES: 
The most commonly investigated techniques to 
prepare microspheres are emulsion solvent 
evaporation techniques, Spray drying, emulsion cross-
linking method Solvent evaporation, Hot melt 
microencapsulation, Solvent removal, Hydrogel 
microspheres and Phase inversion 
Microencapsulation. 
A. Emulsion cross-linking method11:  
The drug was dissolved in an aqueous gelatin solution 
(10% w/v), which was preheated at 40° for 1 h. The 
solution was added drop wise to liquid paraffin while 
stirring the mixture at 1500 rpm at 35° for 10 m. This 
gives water in oil (W/O) emulsion. Stirring was 
continued for further 10 m at 15° and the 
microspheres were washed three times with acetone 
and isopropyl alcohol, respectively. The washed 
microspheres were air dried and then dispersed in 5 ml 
of aqueous glutaraldehyde-saturated toluene solution 
(25% v/v) at room temperature for 3 h to allow cross 
linking. The microspheres were washed with toluene 
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and treated with 100 ml of 10 mM glycine solution 
containing 0.1% w/v Tween 80 at 37° for 10 m to 
block unreacted glutaraldehyde. The resultant 
microspheres were finally freeze-dried.  
B. Solvent Evaporation12:  
It is the most extensively used method of 
microencapsulation, first described by Ogawa et al. A 
buffered or plain aqueous solution of the drug (may 
contain a viscosity building or stabilizing agent) is 
added to an organic phase consisting of the polymer 
solution in solvents like dichloromethane (or ethyl 
acetate or chloroform) with vigorous stirring to form 
the primary water in oil emulsion. This emulsion is 
then added to a large volume of water containing an 
emulsifier like PVA or PVP to form the multiple 
emulsions (w/o/w). The double emulsion, so formed, 
is then subjected to stirring until most of the organic 
solvent evaporates, leaving solid microspheres. The 
microspheres can then be washed, centrifuged and 
lyophilize to obtain the free flowing and dried 
microspheres. 
C. Hot Melt Microencapsulation13: 
This method was first used by Mathiowitz and Langer 
to prepare microspheres of polyanhydride copolymer 
of poly [bis(p-carboxy phenoxy) propane anhydride] 
with sebacic acid. In this method, the polymer is first 
melted and then mixed with solid particles of the drug 
that have been sieved to less than 50m m. The mixture 
is suspended in a non-miscible solvent (like silicone 
oil), continuously stirred, and heated to 5° above the 
melting point of the polymer. Once the emulsion is 
stabilized, it is cooled until the polymer particles 
solidify. The resulting microspheres are washed by 
decantation with petroleum ether. The primary 
objective for developing this method is to develop a 
microencapsulation process suitable for the water 
labile polymers, e.g. polyanhydrides. Microspheres 
with diameter of 1-1000m m can be obtained and the 
size distribution can be easily controlled by altering 
the stirring rate. The only disadvantage of this method 
is moderate temperature to which the drug is exposed. 
D. Solvent Removal14: 
 It is a non-aqueous method of microencapsulation, 
particularly suitable for water labile polymers such as 
the polyanhydrides. In this method, drug is dispersed 
or dissolved in a solution of the selected polymer in a 
volatile organic solvent like methylene chloride. This 
mixture is then suspended in silicone oil containing 
span 85 and methylene chloride. After pouring the 
polymer solution into silicone oil, petroleum ether is 
added and stirred until solvent is extracted into the oil 
solution. The resulting microspheres can then be dried 
in vacuum. 
E. Hydrogel Microspheres15: 
Microspheres made of gel-type polymers, such as 
alginate, are produced by dissolving the polymer in an 
aqueous solution, suspending the active ingredient in 
the mixture and extruding through a precision device, 
producing micro droplets which fall into a hardening 
bath that is slowly stirred. The hardening bath usually 
contains calcium chloride solution, whereby the 
divalent calcium ions crosslink the polymer forming 
gelled microspheres. The method involves an “all-
aqueous” system and avoids residual solvents in 
microspheres. Lim and Moss developed this method 
for encapsulation of live cells, as it does not involve 
harsh conditions, which could kill the cells. The 
surface of these microspheres can be further modified 
by coating them with polycationic polymers, like 
polylysine after fabrication. The particle size of 
microspheres can be controlled by using various size 
extruders or by varying the polymer solution flow 
rates. 
F. Spray Drying16: 
In this process, the drug may be dissolved or dispersed 
in the polymer solution and spray dried. The quality of 
spray-dried microspheres can be improved by the 
addition of plasticizers, e.g. citric acid, which promote 
polymer coalescence on the drug particles and hence 
promote the formation of spherical and smooth 
surfaced microspheres. 
The size of microspheres can be controlled by the rate 
of spraying, the feed rate of polymer drug solution, 
nozzle size, and the drying temperature. This method 
of microencapsulation is particularly less dependent 
on the solubility characteristics of the drug and 
polymer and is simple, reproducible, and easy to scale 
up. 
G. Phase Inversion Microencapsulation17: 
The process involves addition of drug to a dilute 
solution of the polymer (usually 1-5%, w/v in 
methylene chloride). The mixture is poured into an 
unstirred bath of strong non-solvent (petroleum ether) 
in a solvent to non-solvent ratio of 1: 100, resulting in 
the spontaneous production of microspheres in the 
size range of 0.5-5.0m m can then be filtered, washed 
with petroleum ether and dried with air. This simple 
and fast process of microencapsulation involves 
relatively little loss of polymer and drug. 
2. CHARACTERIZATION OF MICROSPHERES: 
A. Particle size, shape and surface morphology 
analysis 18-20:  
All the microspheres were evaluated with respect to 
their size and shape using optical microscope fitted 
with an ocular micrometer and a stage micrometer. 
The particle diameters of more than 100 microspheres 
were measured randomly by optical microscope. The 
average particle size was determined by using the 
Edmondson's equation D mean = εnd/εn, where n= 
number of microspheres observed and d= mean size 
range. The shape and surface morphology of the 
microspheres was studied by using a scanning electron 
microscope.  
B. Entrapment efficiency11,21 : 
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To determine the incorporation efficiency, 25 mg of 
propranolol loaded microspheres were washed with 10 
ml of suitable solvent to remove the surface associated 
drug. The microspheres were then digested in 10 ml of 
suitable solvent for 12 h at room temperature (25±20) 
to release the entrapped drug. Drug content was 
determined spectrophotometrically.  
C. Swelling index 22,25: 
Swelling index was determined by measuring the 
extent of swelling of microspheres in a particular 
solvent. To ensure the complete equilibrium, exactly 
weighed 100 mg of microspheres were allowed to 
swell in solvent for 34 h. The excess surface adhered 
liquid drops were removed by blotting and the swollen 
microspheres were weighed by using microbalance. 
The Hydrogel microspheres then dried in an oven at 
60° for 5 h until there was no change in the dried mass 
of sample. The swelling index of the microsphere was 
calculated by using the formula swelling index= (mass 
of swollen microspheres-mass of dry 
microspheres/mass of dried microspheres) ×100. 
D. In vitro bioadhesion24: 
Bio-adhesive properties of microspheres were 
evaluated using everted sac technique. 
E. In vitro drug release 11,24 :  
To carry out the in vitro drug release, accurately 
weighed drug-loaded microspheres were dispersed in 
dissolution medium in a beaker and maintained at 
37±2° under continuous stirring at 50 rpm. At selected 
time intervals 5 ml samples were withdrawn through a 
hypodermic syringe fitted with a 0.4 mm Millipore 
filter and replaced with the same volume of pre-
warmed fresh dissolution medium to maintain a 
constant volume of the receptor compartment. The 
samples were analyzed spectrophotometrically. 
F. Stability studies of microspheres26, 27:  
All the batches of microspheres were tested for 
stability. The preparations were divided into 3 sets and 
were stored at 4° (refrigerator), room temperature and 
40° (thermostatic oven). After 15, 30 and 60 days, 
drug content of all the formulations was determined 
by the method discussed previously in entrapment 
efficiency section.  
3. VARIABLES INFLUENCING DRUG release 
pattern OF MICROSPHERES: 
There are following factors which directly/indirectly 
affect the drug release characteristics of the 
microspheres; 
 
Figure 1: Variables affecting drug release from microspheres (↑→ Increase release rate, ↓→Decrease release rate) 
A. Concentration of the polymer in dispersed phase: 
Results from different study shows that the particle 
size, swelling, loading efficiency and rate of drug 
release from the microspheres depended on the 
polymer concentration and the type of polymer used. 
Polymer concentration in aqueous phase indirectly 
affects the mucoadhesion time and drug release. As 
the polymer concentration in aqueous phase increases, 
size of microspheres is increased which results 
increase of mucoadhesion time and slower drug 
release from microspheres. 28 
Agrawal et al studied the effects of variables such as 
polymer concentration on the particle size, drug 
release and loading efficiency of microspheres at 
increasing Polymer concentrations (i.e., at drug–
Polymer ratios from 1:2 to 1:6) increased from 135.3 
to 163.4 mm. This increase in particle size of the 
microspheres can be attributed to an increase in 
viscosity with increasing polymer concentrations, 
which resulted in larger emulsion droplets and finally 
in greater microsphere Size. The release of 
albendazole from microspheres decreased as the 
Polymer concentration increased, suggesting that drug 
release could be controlled by varying the Polymer 
concentration. The results might also be explained by 
the fact that the higher Polymer content resulted in 
larger particles with proportionately less drug, so that 
the drug–polymer ratio was changed and thus release 
was reduced. 29 
The decrease in release rate with increasing content of 
the polymer can be explained by a decreased amount 
of drug present close to the surface and also by the 
fact that the amount of uncoated drug decreases with 
increase in polymer concentration 30. When Eudragit® 
RL was used in combination with Eudragit RS, the 
drug released at a faster rate compared to Eudragit® 
RS alone. This is due to the fact that the amount of 
quaternary ammonium groups of Eudragit® RS is 
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lower than that of Eudragit RL, which renders Eudragit® RS is less Permeable 31. 
 
Figure 2: Shows effect of polymer concentration on Drug Release of microspheres28 
Results from study by Lakshmana Prabu S et al 
revealed that the drug content of microspheres was not 
affected by the volume of dichloromethane, but the 
particle sizes were found to change significantly. This 
may also be due to the increase in the volume of 
dichloromethane leads to decrease in viscosity of the 
internal phase could be an effective factor in the droplet 
size of the emulsion in the aqueous medium. In this 
case, it seems that the shear effect of the propeller is 
able to break the large droplets into smaller ones, which 
are solidified into microspheres on solvent evaporation. 
32 
 
Figure 3: Effect of PLGA type on in vitro drug release 34 
Mazumder et al compare the dissolution profiles 
studies and found that drug release from cellulose 
acetate microspheres is faster than ethyl-cellulose 
microspheres. This could be due to high affinity to 
water for cellulose acetate than ethyl-cellulose. 33 
Dhakar et al studied that SCMC microspheres showed 
the faster drug release than drug release from HPMC 
microspheres due to rapid swelling property and high 
dissolution of SCMC in dissolution environment (0.1 
N HCl) as compared to HPMC. Dissolution medium 
permeation in to the microspheres is facilitated due to 
high swelling action of the SCMC which leads to 
more medium for the transport of the drug is 
available.1 
Yaju Ji et al investigate that typical drug release 
profiles of MEP421 PLGA microspheres exhibited 
significant “burst” release followed by slow drug 
release for over one month (Figure 3). Although, the 
microspheres with the high viscosity PLGA (IV = 
0.87 dl/g) showed the lowest “burst” release (not more 
than 10% in the first 24 h), the drug release rate was 
also slow.  
Even after 30 d of in vitro release, the cumulative drug 
release was less than 50% of the total drug loaded. 
Hence, polymer blends of PLGAs with various 
monomer ratios and viscosity were used as matrix 
materials for microspheres in further investigations in 
order to reduce the “burst release”. By using blends of 
different viscosity PLGAs as matrix material for the 
microspheres, the burst release in the first 24 h could 
be limited to less than 20% of the total drug loaded, 
but the disadvantage was that the drug release rate was 
inevitably decreased at the same time (Figure 4). 34 
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Figure 4: In vitro drug release of microspheres prepared using PLGA mixture 34 
Results from in vitro release tests show that clodronate 
release rate from microspheres seems to be affected 
mainly by copolymer MW. A significantly slower drug 
release rate is shown from microspheres of low MW 
copolymers compared to microspheres of high MW 
copolymers respectively. 35 
B. Drug: Polymer Ratio (DPR): 
Effect of DPR on drug release from microspheres by 
Soni et al is shown that rate and extent of release is 
decrease with relative increase in the polymer 
concentration and this can be attributed to the increase 
in the density of the polymer matrix with increased 
polymer concentration. 36 
Drug release from microspheres is notably affected by 
the ratio of the drug to the polymer as increasing in the 
first causes faster drug release. By increasing the 
amount of drug loading, a point will be reached when 
the solid drug particles upon dissolution will begin to 
form continuous pores or channels within the matrix. 
Under these circumstances, the path of release for drug 
molecules will be diffusion within the channels formed 
from areas where drug has previously leached out from 
the matrix 37,38. In other words, as the amount of drug 
content is increased the matrix will become more 
porous as drug is leached out from the polymer and 
thus faster drug release rate occurs 39. 
At lower drug-polymer ratios, the mean particle size of 
the micropellets was less than that at higher drug-
polymer ratios. Therefore, the drug release from 
micropellets prepared at lower drug- polymer ratios 
was faster than that of micropellets prepared at higher 
drug-polymer ratios because of the small size of the 
micropellets, which provided a large surface area for 
faster drug release. 40 
Dissolution profiles from study by Mazumder et al 
indicate that when drug to polymer ratio decreased 
from 1:1 to 1:3 a decreased in release rate was 
observed. It is considered that higher the drug to 
polymer ratio in the microspheres, result in increased in 
coat thickness surrounding the drug particles thereby 
increasing the distance traveled by the drug through 
coat 41-43.  
C. Effect of Temperature:  
Microspheres prepared at 60°C showed faster drug 
release than the microspheres prepared at 10°C. This 
can be attributed to the decrease in viscosity of the oily 
phase as the temperature increases, which in turn 
decrease the microspheres. 40 
D. Selection of solvent system for the dispersed phase 
Selection of solvent system based on the volatility of 
solvent, solubility of polymer and type of method of 
preparation used for preparation of microspheres. 
Solvent should have high volatility and high polymer 
solubility.  
Park et al. were prepared lysozyme-loaded PLGA 
microparticles using the oil in water (o/w) single 
emulsion technique. Here, the authors used a co-solvent 
system, varying the ratio of the component solvents. 
DMSO was used for solubilization of lysozyme and 
PLGA, and methylene chloride was used for generation 
of emulsion drops as well as solubilization of PLGA. 
Encapsulation efficiency increased, and initial burst 
decreased as the volume fraction of DMSO in the co-
solvent system increased. Particle size increased, and 
density of the microparticle matrix decreased with 
increasing DMSO. Overall, these results indicate that 
the presence of DMSO increased the hydrophilicity of 
the solvent system and allowed fast extraction of the 
solvent into the continuous phase, which led to higher 
encapsulation efficiency and larger particle size 44. 
Larger particle size indirectly slower the drug release 
from micoepheres. 
E. Ratio of dispersed phase to continuous phase (D/C 
ratio): 
No significant difference in particle size was observed 
(P > 0.05). All microspheres have a spherical shape 
without pores on the surface, with size approximately 
20 µm. However, the drug loading and encapsulation 
efficiency increased remarkably with decreasing D/C 
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ratio (P < 0.05) 45. Similar phenomena were reported 
for the encapsulation of progesterone 45. Additionally, 
the surface of microspheres was smoother at lower D/C 
ratios, probably due to the faster solidification rate. It 
has been reported that the porosity in a system of 
microspheres is determined during microspheres 
hardening as the organic solvent evaporates during 
preparation 46. Continuous phase containing a large 
amount of water resulted in faster polymer precipitation 
and therefore less porous spheres were formed 47. 
As volume of continuous phase is increased, the size of 
microspheres decreased which results in decrease in 
loading efficiency, less mucoadhesion time and faster 
drug release. 28 
Study from Mazumder shows that when the volume of 
external phase was increased from 50 ml to 100 ml, an 
increased in release rate significantly (p < 0.05 
Student’s t-test). This is due to higher migration of drug 
due to free movement of emulsion droplets, when the 
volume of external processing medium was increased. 
33
 
F. Effect of concentration of emulsifier: 
Agrawal et al studied the effects of concentrations of 
emulsifier on the chracteristics of microspheres. The 
mean diameter of the microspheres at increasing 
concentrations of emulsifier (i.e., 0.50, 0.75, 1.00, and 
1.25%) decreased as 152.6, 147.1, 142.4, and 132.7 
mm, respectively. The more emulsifier added, the less 
irregular were the microspheres, and the size of the 
microspheres was reduced. This appears to have 
resulted from a tightening of polymeric network, 
leading to microsphere shrinkage as the concentration 
of emulsifier is increased. Decrease in particle size 
results in faster drug release 29. 
Mahboubian et al has prepared PLGA microspheres of 
triptoline. Results from study showed that higher 
amount of Span 20 (10%) led to a faster drug release 
rate by increasing the hydrophilic channels inside the 
hydrophobic PLGA matrix 48. 
G. Effect concentration of cross linking agent: 
Experimental cross-linking conditions (time and 
amount of the cross-linking agent) varyingly affected 
the Appearance of the microspheres surface, their mean 
particle size, drug loading and drug release of 
microspheres. The swelling ratio of microspheres 
increased dramatically when a smaller amount of cross-
linking agent was used.  
As shown in Figure 5, by increasing the concentration 
of glutaraldehyde-saturated toluene from 12 to 35% 
(V/V), the amount of drug release decreased from 30 to 
10% in the first 30 minutes of the drug release 
experiment. The same pattern was observed when the 
duration of cross-linking was altered, i.e., the longer the 
time of cross-linking the lower was the ratio of 
swelling. Results also shown that by decreasing the 
cross-linking time from 12 to 1 hour, the amount of 
drug release in the first 30 minutes was increased by 12 
to 42% 49.  For batches cross-linked with 35% (V/V) 
glutaraldehyde-saturated toluene and 4 hours of cross-
linking time period, t50 and t85 of drug release were 40 
and 480 minutes, respectively. This type of release 
profile is of interest because the initial burst release can 
provide the initial penetration of lactic acid, and the 
sustained release phase supplies the skin with the drug 
over a prolonged period of time 50. The initial burst 
drug release may be attributed to the release of drug 
molecules held loosely into or just beneath the surface 
of microspheres. Such a burst effect was reported 
previously for gelatin microspheres 51-52. 
 
Figure 5: Effect of Concentration of Crosslink agent and cross linking time on drug release profile 49 
Tayade et al prepared the micropellets containing 
ibuprofen by cross-linking technique using gelatin 
polymer. The micropellets treated with formalin vapors 
for a longer period of time showed slower drug release as 
compared to micropellets treated for a shorter period of 
time. This result may be attributed to the higher degree of 
cross-linking of gelatin, when exposed to formalin vapors 
for a longer period of time, which retarded a drug release 
from the pellets40. 
H. Effect of stirring speed:  
The drug release rate was increasing on increasing the 
stirring rate. Drug release was higher in the case of 
microspheres prepared at a higher stirring rate but at low 
stirring rate the release rate was slow. This can be 
attributing that smaller size microspheres have a larger 
surface area exposed to dissolution medium, giving rise to 
faster drug release 54 
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Mazumder et al investigated that drug release was 
increased significantly (p < 0.05 Student’s t-test) with 
increasing in stirring speed. When the stirring speed 
decreased from 1200 rpm to 600 rpm an initial burst 
release of around 38.45 % to 50.25 % occurred within 2 
hours 33. This can be attributed to the fact that the drug 
migration will be high for low stirrer speed and more 
amount of drug will remain in the microspheres surface 
but when stirring speed was increased drug migration will 
be less due to collision of emulsion droplets 54. 
Dhakar et al studied the effect of stirring on the 
characteristics of metformin HCl microspheres. Results 
indicate that drug release rate is increased as increase in 
stirring speed. This is attributing the fact that increase in 
stirring speed leads to decrease in particle size which 
provide larger surface area for the dissolution 1. 
 
Figure 6: Effect of stirring speed on drug release of 
microspheres 1 
 
CONCLUSION:  
For many drugs, microsphere technology offers an 
effective alternative to conventional oral and nasal 
delivery. The well designed microspheres technologies do 
away with various limitations i.e. poor surface 
morphology, low loading efficiency and unexpected drug 
release kinetics and open a completely new option for 
delivery of wide variety of therapeutics. Interestingly, 
literature survey revealed that the rates of Drug release 
significantly affect by polymer concentration, drug to 
polymer ratio, amount and type of cross linking agent, 
concentration of emulsifier, swelling index of polymer 
and many other variables. The purpose of this work was 
to understanding effect of various process as well as 
formulation variables on the encapsulation efficiency of 
the microspheres. This review will focus on how the 
formulation variables of microspheres formulation affect 
the drug entrapment efficiency the microspheres. This 
paper also explains that how drug entrapment efficiency 
depend upon particle size, Polymer concentration, type of 
polymer, drug: polymer ratio, DP: CP ratio, drug: 
polymer interaction, solubility of polymer as well as drug, 
method of preparation etc. This will only possible by 
understanding the effect of various variables which affect 
the drug entrapment efficiency of these microspheres. 
Progress to date suggests that microspheres technology 
can continue to expand and become an increasingly 
important drug delivery system for wide variety of 
therapeutics. 
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